Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Hiroyoshi Yamazaki, Noriko Kobayashi, Masanori Taketsuna, Koyuki Tajima & Masahiro Murakami. (2017) Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data. Current Medical Research and Opinion 33:5, pages 963-971.
Read now
Read now
Adam M Henrie, James J Nawarskas & Joe R Anderson. (2015) Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evidence 10, pages 99-109.
Read now
Read now
Maria Klara Frey & Irene Lang. (2012)
Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 13:5, pages 747-755.
Read now
Read now
Jeremy A Falk, Kiran J Philip & Ernst R Schwarz. (2010) The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vascular Health and Risk Management 6, pages 273-280.
Read now
Read now
Articles from other publishers (25)
Ahmed K. ElHady, Dalia S. El-Gamil, Mohammad Abdel-Halim & Ashraf H. Abadi. (2023) Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives. Pharmaceuticals 16:9, pages 1266.
Crossref
Crossref
Sumon Roy, Robert A. Kloner, Fadi N. Salloum & Ion S. Jovin. (2021) Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. Cardiovascular Drugs and Therapy 37:4, pages 793-806.
Crossref
Crossref
Barbara Stollfuss, Manuel Richter, Daniel Drömann, Hans Klose, Martin Schwaiblmair, Ekkehard Gruenig, Ralf Ewert, Martin C Kirchner, Frank Kleinjung, Valeska Irrgang & Christian Mueller. (2021) Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP). Journal of Medical Internet Research 23:10, pages e25163.
Crossref
Crossref
Layse Nakazato, Felipe Mendes, Ilma A. Paschoal, Daniela C. Oliveira, Marcos M. Moreira & Mônica C. Pereira. (2021) Association of daily physical activity with psychosocial aspects and functional capacity in patients with pulmonary arterial hypertension: a cross‐sectional study. Pulmonary Circulation 11:2, pages 1-9.
Crossref
Crossref
Paresh C. Giri, Gizelle J. Stevens, Jeanette Merrill‐Henry, Udochukwu Oyoyo & Vijay P. Balasubramanian. (2021) Participation in pulmonary hypertension support group improves patient‐reported health quality outcomes: a patient and caregiver survey. Pulmonary Circulation 11:2, pages 1-11.
Crossref
Crossref
Silvia Ulrich & Ekkehard Grunig. (2021) The patient tells it! The importance of patient's quality of life perception in pulmonary arterial hypertension risk assessment. European Respiratory Journal 57:2, pages 2004376.
Crossref
Crossref
Hayley Barnes, Zoe Brown, Andrew Burns & Trevor Williams. (2019) Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
Michael D. McGoon, Pisana Ferrari, Iain Armstrong, Migdalia Denis, Luke S. Howard, Gabi Lowe, Sanjay Mehta, Noriko Murakami & Brad A. Wong. (2019) The importance of patient perspectives in pulmonary hypertension. European Respiratory Journal 53:1, pages 1801919.
Crossref
Crossref
Ghaleb Khirfan, Adriano R. Tonelli, Jennifer Ramsey & Sandeep Sahay. (2018) Palliative care in pulmonary arterial hypertension: an underutilised treatment. European Respiratory Review 27:150, pages 180069.
Crossref
Crossref
Debasree Banerjee, Sara E. Vargas, Kate M. Guthrie, Brittany M. Wickham, Melissa Allahua, Mary E. Whittenhall, Amy J. Palmisciano & Corey E. Ventetuolo. (2018) Sexual health and health‐related quality of life among women with pulmonary arterial hypertension. Pulmonary Circulation 8:4, pages 1-10.
Crossref
Crossref
Katherine Alexis Athanasiou, Sonu Sahni, Amrinder Rana & Arunabh Talwar. (2017) Diagnosing and managing scleroderma-related pulmonary arterial hypertension. JAAPA 30:9, pages 11-18.
Crossref
Crossref
Shuyan Gu, Huimei Hu & Hengjin Dong. (2016) Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension. PharmacoEconomics 34:8, pages 751-770.
Crossref
Crossref
Stephen C. Mathai, Tomeka Suber, Rubina M. Khair, Todd M. Kolb, Rachel L. Damico & Paul M. Hassoun. (2016) Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society 13:1, pages 31-39.
Crossref
Crossref
Marion Delcroix & Luke Howard. (2015) Pulmonary arterial hypertension: the burden of disease and impact on quality of life. European Respiratory Review 24:138, pages 621-629.
Crossref
Crossref
Stephen C. Mathai, Paul M. Hassoun, Milo A. Puhan, Yi Zhou & Robert A. Wise. (2015) Sex Differences in Response to Tadalafil in Pulmonary Arterial Hypertension. Chest 147:1, pages 188-197.
Crossref
Crossref
Caio JCS Fernandes, Barbara CS Martins, Carlos VP Jardim, Rozana M Ciconelli, Luciana K Morinaga, Ana Paula Breda, Susana Hoette & Rogério Souza. (2014) Quality of life as a prognostic marker in pulmonary arterial hypertension. Health and Quality of Life Outcomes 12:1.
Crossref
Crossref
Luke S. Howard, Pisana Ferrari & Sanjay Mehta. (2014) Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?. European Respiratory Review 23:134, pages 458-468.
Crossref
Crossref
Yasutomo Hori, Chigusa Kondo, Maho Matsui, Maki Yamagishi, Shozo Okano, Seishiro Chikazawa, Kazutaka Kanai, Fumio Hoshi & Naoyuki Itoh. (2014) Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension. The Veterinary Journal 202:2, pages 334-339.
Crossref
Crossref
Gilles Rival, Yves Lacasse, Sylvie Martin, Sébastien Bonnet & Steeve Provencher. (2014) Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life. Chest 146:3, pages 686-708.
Crossref
Crossref
Michael Halank, Franziska Einsle, Stephanie Lehman, Hinrich Bremer, Ralf Ewert, Heinrike Wilkens, F. Joachim Meyer, Ekkehard Grünig, Hans-Jürgen Seyfarth, Martin Kolditz, Gesine Wieder, Gert Höffken & Volker Köllner. (2013) Exercise Capacity Affects Quality of Life in Patients with Pulmonary Hypertension. Lung 191:4, pages 337-343.
Crossref
Crossref
Dioma U. Udeoji & Ernst R. Schwarz. (2012) Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease 7:1, pages 39-49.
Crossref
Crossref
Stephen C. Mathai, Milo A. Puhan, Diana Lam & Robert A. Wise. (2012) The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine 186:5, pages 428-433.
Crossref
Crossref
Javier Gaudó Navarro & Antonio Sueiro Bendito. (2011) Tadalafilo: nuevos aspectos de la inhibición de la fosfodiesterasa tipo 5 en el tratamiento de la hipertensión pulmonar. Archivos de Bronconeumología 47, pages 26-31.
Crossref
Crossref
Heidi B. Kellihan & Rebecca L. Stepien. (2010) Pulmonary Hypertension in Dogs: Diagnosis and Therapy. Veterinary Clinics of North America: Small Animal Practice 40:4, pages 623-641.
Crossref
Crossref
Jamie D. Croxtall & Katherine A. Lyseng-Williamson. (2010) Tadalafil. Drugs 70:4, pages 479-488.
Crossref
Crossref